Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Forest Laboratories reports patent re-examination

Forest Laboratories reports patent re-examination

8th September 2008

Forest Laboratories has announced that an office action in the re-examination of the patent for nebivolvol, the active ingredient in beta blocker Bystolic has been received.

The office action received from the US Patent and Trademark Office (USPTO) by Janssenn Pharmaceutica, the holder of US Patent No. 6,545,040.

“In the office action, the USPTO has rejected all of the pending claims as unpatentable in view of the cited prior art,” Forest Laboratories said.

It added that it believed all claims are patentable over the cited art and resolved to continue the prosecution of this re-examination application.

While the firm said it could not give an assurance of success in this matter, it restated its confidence over the strength over the patent covering the compound.

Earlier this month, Forest Laboratories and Laboratorios Alimirall announced positive phase III results from a phase III study of aclidinium bromide as a treatment for chronic obstructive pulmonary disease patients.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.